Rifampicin/isoniazid/pyrazinamide

Rifampicin/isoniazid/pyrazinamide

Combination of
Rifampicin	Rifamycin antibiotic
Isoniazid	First-line anti-tuberculosis medication
Pyrazinamide	Anti-tuberculosis medication
Clinical data
Trade names	Rifater, Trifazid
AHFS/Drugs.com	FDA Professional Drug Information
Pregnancy category	C
Legal status	℞ (Prescription only)
Routes of administration	Oral
Identifiers
ATC code	J04AM05 (WHO)
PubChem	CID: 6474062
(verify)

Rifampicin/isoniazid/pyrazinamide (trade name Rifater) is a fixed dose combination tablet manufactured by Aventis used in the treatment of tuberculosis. Each tablet contains 120 mg rifampicin, 50 mg isoniazid and 300 mg pyrazinamide. It is used in initial treatment of tuberculosis, typically for the first two months.

Rifater is contraindicated in children with a body weight of under 40 kg.

The purpose of the fixed dose combination is to make it easier for patients to take their medication; but also to ensure that if patients forget to take one or two of their drugs, they do not then develop resistance to the remaining drugs.

See also

• Tuberculosis treatment